Pembrolizumab + Cisplatin
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Negative
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
Trial Timeline
Apr 1, 2019 → Oct 30, 2022
NCT ID
NCT03644589About Pembrolizumab + Cisplatin
Pembrolizumab + Cisplatin is a phase 2 stage product being developed by Merck for Estrogen Receptor Negative. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03644589. Target conditions include Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor Negative were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03644589 | Phase 2 | Withdrawn |
| NCT03383094 | Phase 2 | Active |
| NCT02635360 | Phase 2 | Completed |
| NCT02777385 | Phase 2 | Completed |
| NCT02759575 | Phase 1/2 | Completed |
| NCT02641093 | Phase 2 | Active |
Competing Products
20 competing products in Estrogen Receptor Negative